Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Euro Surveill ; 20(32): 2-5, 2015 Aug 13.
Artículo en Inglés | MEDLINE | ID: mdl-26290486

RESUMEN

We report an imported case of louse-borne relapsing fever in a young adult Eritrean refugee who presented with fever shortly after arriving in Switzerland. Analysis of blood smears revealed spirochetes identified as Borrelia recurrentis by 16S rRNA gene sequencing. We believe that louse-borne relapsing fever may be seen more frequently in Europe as a consequence of a recent increase in refugees from East Africa travelling to Europe under poor hygienic conditions in confined spaces.


Asunto(s)
Borrelia/aislamiento & purificación , ARN Ribosómico 16S/genética , Fiebre Recurrente/diagnóstico , Animales , Borrelia/genética , Ceftriaxona/administración & dosificación , ADN Bacteriano/genética , Doxiciclina/administración & dosificación , Eritrea , Humanos , Refugiados , Fiebre Recurrente/sangre , Fiebre Recurrente/tratamiento farmacológico , Suiza , Viaje , Resultado del Tratamiento
2.
Eur J Med Res ; 12(2): 54-60, 2007 Feb 26.
Artículo en Inglés | MEDLINE | ID: mdl-17369118

RESUMEN

BACKGROUND: Nucleoside analogues such as Didanosine and Stavudine are known to cause metabolic and body habitus changes during antiretroviral therapy. The most frequently observed are lactic acidosis, hypercholesterinaemia, hypertriglyceridaemia and lipodystrophy. METHODS: Over one year we monitored a cohort of 43 patients who switched from either Stavudine, Didanosine or the combination of both to Tenofovir. A group of 11 patients was kept on their original regimen and acted as control group. Blood samples were taken every 3 months from baseline, anthropometric measurements were performed at baseline, after 6 and 12 months. RESULTS: During observation the levels of lactic acid and cholesterol decreased significantly in the switch group while virologic and immunologic efficacy remained stable. Serum creatinine levels rose significantly in patients switched to Tenofovir, but remained within physiological limits. The mean skin fold thickness increased significantly by 1.8 mm in the switch group after 6 months (p < or =0.001 - p = 0.032). CONCLUSION: These results implicate an improvement of lipid profiles, serum lactate and lipodystrophy in HIV-positive patients after switch to Tenofovir. As a moderate increase in serum creatinine levels was observed, the renal function of patients on a Tenofovir-based regimen should be monitored closely.


Asunto(s)
Adenina/análogos & derivados , Didanosina/uso terapéutico , Infecciones por VIH/tratamiento farmacológico , Organofosfonatos/uso terapéutico , Grosor de los Pliegues Cutáneos , Estavudina/uso terapéutico , Adenina/efectos adversos , Adenina/uso terapéutico , Adulto , Anciano , Fármacos Anti-VIH/efectos adversos , Fármacos Anti-VIH/uso terapéutico , Peso Corporal , Recuento de Linfocito CD4 , Colesterol/sangre , HDL-Colesterol/sangre , LDL-Colesterol/sangre , Creatinina/sangre , Didanosina/efectos adversos , Femenino , Tasa de Filtración Glomerular , Hemoglobina Glucada , Infecciones por VIH/sangre , Infecciones por VIH/metabolismo , Hemoglobinas/análisis , Humanos , Ácido Láctico/sangre , Masculino , Persona de Mediana Edad , Organofosfonatos/efectos adversos , Fosfatos/sangre , Estavudina/efectos adversos , Tenofovir , Resultado del Tratamiento , Triglicéridos/sangre , Ácido Úrico/sangre , Carga Viral
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...